SERENOX LIMITED

Company Registration Number:
14255266 (England and Wales)

Unaudited abridged accounts for the year ended 31 December 2023

Period of accounts

Start date: 25 July 2022

End date: 31 December 2023

SERENOX LIMITED

Contents of the Financial Statements

for the Period Ended 31 December 2023

Company Information - 3
Report of the Directors - 4
Profit and Loss Account - 5
Balance sheet - 6
Additional notes - 8

SERENOX LIMITED

Company Information

for the Period Ended 31 December 2023




Director: Annette Hildegard Schuh
Steven John Powell
Secretary: Steven Powell
Registered office: Hampden House,
Monument Business Park,
Warpsgrove Lane, Chalgrove,
Oxford,
Oxfordshire,
GBR
OX44 7RW
Company Registration Number: 14255266 (England and Wales)

SERENOX LIMITED

Directors' Report Period Ended 31 December 2023

The directors present their report with the financial statements of the company for the period ended 31 December 2023

Principal Activities

Serenox’s principal activity is to save the lives by leveraging our intellectual property and know-how to enable precise and rapid diagnosis of inherited blood disorders, infectious diseases and early-stage cancer in sub-Saharan Africa

Directors

The director(s) shown below were appointed to the company during the period
Annette Hildegard Schuh
25 July 2022
Steven John Powell
25 July 2022

Secretary
Steven Powell

This report was approved by the board of directors on 3 April 2024
And Signed On Behalf Of The Board By:

Name: Steven John Powell
Status: Director

SERENOX LIMITED

Profit and Loss Account

for the Period Ended 31 December 2023


Notes
17 months to
31 Dec 2023
£
Gross Profit or (Loss) 0
Income from coronavirus (COVID-19) business support grants 0
Distribution Costs ( 0 )
Administrative Expenses ( 36,641 )
Operating Profit or (Loss) ( 36,641 )
Interest Receivable and Similar Income 0
Interest Payable and Similar Charges ( 0 )
Profit or (Loss) Before Tax ( 36,641 )
Profit or (Loss) for Period ( 36,641 )

The notes form part of these financial statements

SERENOX LIMITED

Balance sheet

As at 31 December 2023


Notes
17 months to
31 Dec 2023
£
Fixed assets
Total fixed assets: -
Current assets
Cash at bank and in hand: 35
Total current assets: 35
Prepayments and accrued income: 7,879
Creditors: amounts falling due within one year: ( 44,470 )
Net current assets (liabilities): ( 36,556 )
Total assets less current liabilities: ( 36,556 )
Total net assets (liabilities): ( 36,556 )

The notes form part of these financial statements

SERENOX LIMITED

Balance sheet continued

As at 31 December 2023


Notes
17 months to
31 Dec 2023
£
Capital and reserves
Called up share capital: 85
Profit and loss account: ( 36,641 )
Shareholders funds: ( 36,556 )

For the year ending 31 December 2023 the company was entitled to exemption under section 477 of the Companies Act 2006 relating to small companies.

The members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.

The members have agreed to the preparation of abridged accounts for this accounting period in accordance with Section 444(2A).

These accounts have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

This report was approved by the board of directors on 3 April 2024
And Signed On Behalf Of The Board By:

Name: Steven John Powell
Status: Director

The notes form part of these financial statements

SERENOX LIMITED

Notes to the Financial Statements

for the Period Ended 31 December 2023

  • 1. Accounting policies

    Basis of measurement and preparation

    These financial statements have been prepared in accordance with the provisions of Section 1A (Small Entities) of Financial Reporting Standard 102

SERENOX LIMITED

Notes to the Financial Statements

for the Period Ended 31 December 2023

  • 2. Employees

    17 months to
    31 Dec 2023
    Average number of employees during the period 0

SERENOX LIMITED

Notes to the Financial Statements

for the Period Ended 31 December 2023

  • 3. Off balance sheet disclosure

    No

SERENOX LIMITED

Notes to the Financial Statements

for the Period Ended 31 December 2023

4.1.Related party disclosures

Name of related party: Steven John Powell
Description of relationship:
Director
Description of the transaction:
Director's Loan to the company
Balance at 31 December 2023 44,470

For the year ended 31 December 2023, £44,470 was owed to S Powell through his personal service company, The Truffaldino Partnership Ltd. Dr Steven Powell is a director and majority shareholder of The Truffaldino Partnership Ltd . The funds provided was used as working capital for the business.